```html

Opsoclonus‑Myoclonus Syndrome (OMS) – A Patient‑Friendly Medical Guide

Overview

Opsoclonus‑myoclonus syndrome (OMS) is a rare neurologic disorder characterized by rapid, involuntary eye movements (opsoclonus) together with brief, shock‑like jerks of the limbs or trunk (myoclonus). It is often accompanied by ataxia (poor coordination), irritability, sleep disturbances, and, in children, developmental regression.

Who it affects

• Children: 70‑80 % of cases occur in children, most commonly between 6 months and 3 years of age.
• Adults: The remaining cases are seen in adults, frequently associated with underlying cancer (paraneoplastic OMS).

Prevalence

• Estimated incidence in children is 1‑3 cases per 1 million children per year (Mayo Clinic, 2023).
• Adult incidence is even lower, with roughly 100–150 new cases reported worldwide annually.

Because OMS is so uncommon, many patients experience a diagnostic delay of several months, underscoring the importance of awareness.

Symptoms

OMS presents with a constellation of neurologic and systemic signs. The severity can range from mild (noticeable tremor) to severe (profound disability). Below is a comprehensive list:

Ocular (Opsoclonus)

• Multidirectional, chaotic eye movements: rapid, arrhythmic saccades that occur without a pause and are not suppressed by fixation.
• Vertigo or visual instability due to constant motion.

Motor (Myoclonus)

• Brief, involuntary jerks of the arms, legs, or trunk, often stimulus‑sensitive.
• Action‑induced myoclonus – jerks become more noticeable when reaching or walking.

Coordination & Balance

• Ataxia: unsteady gait, frequent falls, difficulty with fine motor tasks (e.g., buttoning).
• Dysmetria: overshooting or undershooting when trying to touch a target.

Behavioral & Cognitive

• Irritability or emotional lability — especially common in infants.
• Sleep disturbances: frequent waking, night terrors.
• Developmental regression in children (loss of language or motor milestones).
• Attention deficits, learning difficulties in older children and adults.

Other Possible Findings

• Fever or mild systemic illness (more common in paraneoplastic adult cases).
• Weight loss or night sweats if an underlying tumor is present.

Causes and Risk Factors

OMS is considered an autoimmune‑mediated disorder. The immune system mistakenly attacks parts of the brainstem and cerebellum that control eye movements and muscle tone.

Primary Causes

• Paraneoplastic OMS (Adults) – most often linked to neuroblastoma in children and to small‑cell lung cancer, breast carcinoma, or ovarian teratoma in adults.<sup>[1]</sup>
• Post‑infectious OMS – following viral infections such as Epstein‑Barr virus, Coxsackie virus, or influenza.<sup>[2]</sup>
• Idiopathic – no identifiable trigger; thought to be a primary autoimmune process.

Risk Factors

• Age < 3 years (children) or > 50 years (adults) – age groups with the highest reported cases.
• Presence of an underlying malignancy, especially neuroblastoma in kids.
• Recent viral illness (within 2–4 weeks).
• Genetic predisposition to autoimmunity (e.g., family history of rheumatologic disease).

Diagnosis

Because OMS mimics other movement disorders, a systematic approach is essential.

Clinical Evaluation

1. History – onset, progression, recent infections, cancer symptoms, family history.
2. Neurologic examination – documentation of opsoclonus, myoclonus, ataxia, and any cognitive changes.

Laboratory Tests

• Complete blood count, metabolic panel – rule out metabolic causes.
• Autoantibody panels (e.g., anti‑Ri, anti‑Hu, anti‑Yo) – may be positive in paraneoplastic OMS.
• Serology for recent infections (CMV, EBV, enterovirus).

Imaging

• MRI of brain – usually normal but helps exclude structural lesions.
• Whole‑body PET/CT or CT scan – in adults or children with suspected neoplasm; neuroblastoma is the most common pediatric tumor.

Electrophysiology

• EEG – often normal; helps rule out epileptic seizures.
• EMG & nerve conduction studies – may show stimulus‑sensitive myoclonus.

Diagnostic Criteria (adapted from NIH consensus)

A diagnosis of OMS is made when a patient has:

1. Opsoclonus + myoclonus (or ataxia) AND
2. No alternative neurological disorder explains the findings, AND
3. Evidence of an autoimmune trigger (tumor, infection, or autoantibodies) OR a “probable idiopathic” presentation.

Treatment Options

Treatment aims to suppress the autoimmune response, control symptoms, and address any underlying tumor.

First‑Line Immunotherapy

• Corticosteroids (e.g., prednisone 2 mg/kg/day, tapered over 6–12 weeks). Rapidly reduces inflammation but relapse is common after taper.
• Intravenous Immunoglobulin (IVIG) – 2 g/kg divided over 2–5 days; often combined with steroids for synergistic effect.
• Plasma Exchange (PLEX) – 5‑7 exchanges over 10‑14 days; useful in refractory cases.

Second‑Line / Steroid‑Sparing Agents

• Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly for 4 weeks; shown to lower relapse rates in pediatric series.<sup>[3]</sup>
• Mycophenolate mofetil – 600 mg/m² twice daily; useful for long‑term maintenance.
• Cyclophosphamide – considered in severe, refractory adult cases.

Symptomatic Medications

• Clonazepam or levetiracetam – can dampen myoclonus.
• Gabapentin – assists with neuropathic pain that may accompany OMS.
• Physical therapy‑guided exercises – improve ataxia and coordination.

Tumor‑Directed Therapy (if applicable)

• Surgical resection of neuroblastoma or other malignancy.
• Adjunct chemotherapy/radiation per oncologic protocols.

Rehabilitation & Supportive Care

• Early involvement of occupational, speech and physical therapists.
• Educational interventions for school‑aged children.
• Psychological counseling for mood and behavioral issues.

Living with Opsoclonus‑Myoclonus Syndrome

Because OMS can affect motor skills, cognition, and emotional health, a multidisciplinary approach improves quality of life.

Daily Management Tips

1. Medication adherence – keep a medication diary; set alarms for IVIG or steroid taper schedules.
2. Safety modifications – install grab bars, non‑slip mats, and use a sturdy wheelchair or walker if balance is poor.
3. Structured routine – predictable sleep/wake patterns reduce irritability.
4. Therapy schedule – attend PT/OT sessions 2‑3 times weekly; practice balance exercises at home.
5. Communication aids – picture boards or speech‑generating devices for children with speech regression.
6. School accommodations – request an Individualized Education Plan (IEP) with extra time for tests and physical‑education modifications.
7. Nutrition – balanced diet supports immune health; consider vitamin D & omega‑3 supplementation after discussing with a clinician.

Support Resources

• National Organization for Rare Disorders (NORD) – patient‑to‑patient forums.
• Opsoclonus‑Myoclonus Syndrome Foundation – educational webinars.
• Local neuro‑immunology clinics with experience in pediatric paraneoplastic syndromes.

Prevention

Because many OMS cases are autoimmune, true primary prevention is limited. However, risk can be reduced by:

1. Prompt treatment of infections – seek medical evaluation for prolonged fevers or viral illnesses, especially in young children.
2. Early detection of neuroblastoma – routine pediatric examinations that note abdominal masses or unexplained weight loss.
3. Avoiding unnecessary immune‑suppressing medications that could trigger dysregulated immunity (consult a physician before starting over‑the‑counter immune boosters).

Complications

If OMS is not adequately treated, several serious outcomes may occur:

• Permanent neurologic deficits – chronic ataxia, persistent myoclonus, visual instability.
• Cognitive and developmental impairment – especially in children; may lead to learning disabilities.
• Psychiatric disorders – anxiety, depression, or behavioral disorders.
• Secondary injury – due to falls, fractures, or head trauma.
• Relapse or progression – up to 60 % of pediatric patients experience at least one relapse after steroid taper.<sup>[4]</sup>
• Complications from underlying malignancy – if a tumor remains undiagnosed, cancer progression reduces survival.

When to Seek Emergency Care

---

**References**

1. Ramanathan R, et al. Paraneoplastic opsoclonus‑myoclonus syndrome: A review of clinical features and management. Autoimmunity Reviews. 2022;21(8):102945.
2. Centers for Disease Control and Prevention. Viral encephalitis. 2023. https://www.cdc.gov/encephalitis/viral.html
3. Cleveland Clinic. Opsoclonus‑Myoclonus Syndrome (OMS). 2023. https://my.clevelandclinic.org/health/diseases/16841-opsoclonus-myosclonus-syndrome
4. Mayo Clinic. Opsoclonus‑myoclonus syndrome. 2024. https://www.mayoclinic.org/diseases-conditions/opsoclonus-myosclonus-syndrome/symptoms-causes/syc-20440223
5. World Health Organization. Rare diseases: Overview. 2022. https://www.who.int/health-topics/rare-diseases

```